CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...
Phase 1
Tacoma, Washington, United States and 12 other locations
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
Seattle, Washington, United States and 25 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Seattle, Washington, United States and 48 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
Seattle, Washington, United States and 9 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Seattle, Washington, United States and 40 other locations
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Seattle, Washington, United States and 31 other locations
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Seattle, Washington, United States and 35 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Seattle, Washington, United States and 59 other locations
phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...
Phase 1, Phase 2
Seattle, Washington, United States and 24 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Seattle, Washington, United States and 211 other locations
Clinical trials
Research sites
Resources
Legal